The WSJ reports that Pfizer (NYSE:PFE) has found a promising coronavirus treatment that works by blocking viral replication. It plans to start testing this summer.
Rheumatoid arthritis med Xeljanz (tofacitinib), a
Janus kinase inhibitor, is another option. Testing in COVID-19 patients
will start this week in Italy.
Also, it intends to publish research on whether one of its antibiotics benefits COVID-19 patients.
Clinical trials should launch this month evaluating a vaccine candidate that it is developing with Germany’s BioNTech SE (NASDAQ:BNTX).
https://seekingalpha.com/news/3559589-pfizer-identifies-lead-covidminus-19-candidate
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.